Loading...
OTCM
NMRD
Market cap8kUSD
Dec 05, Last price  
0.00USD
1D
0.00%
Jan 2017
-100.00%
IPO
-99.99%
Name

Nemaura Medical Inc

Chart & Performance

D1W1MN
OTCM:NMRD chart
P/E
P/S
0.10
EPS
Div Yield, %
Shrs. gr., 5y
-30.19%
Rev. gr., 5y
%
Revenues
77k
-84.71%
000000000503,90677,044
Net income
-14m
L+1.85%
-830,574-586,233-1,319,840-1,539,637-1,551,266-1,820,449-4,452,797-4,160,196-6,258,596-13,886,805-14,143,735
CFO
-8m
L+29.95%
-768,3061,504,830-1,432,863-1,209,365-1,192,828-2,136,977-3,560,952-3,449,545-5,998,097-6,504,041-8,451,781

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
IPO date
Nov 04, 2014
Employees
36
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT